Immix Biopharma
IMMX
25 hedge funds and large institutions have $6.1M invested in Immix Biopharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
550% more call options, than puts
Call options by funds: $13K | Put options by funds: $2K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
1.86% less ownership
Funds ownership: 16.77% → 14.92% (-1.9%)
19% less funds holding
Funds holding: 31 → 25 (-6)
30% less capital invested
Capital invested by funds: $8.77M → $6.1M (-$2.67M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$201K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$169K |
| 3 |
Morgan Stanley
New York
|
+$52K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$16K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$570K |
| 2 |
Renaissance Technologies
New York
|
-$306K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$64K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$62.1K |
| 5 |
Squarepoint
New York
|
-$45.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$306K | -154,685 | Closed |
|
|
FIA
27
FNY Investment Advisers
New York
| – | -$64K | -32,500 | Closed |
|
|
28
Squarepoint
New York
| – | -$45.6K | -23,010 | Closed |
|
|
XT
29
XTX Topco
George Town,
Cayman Islands
| – | -$35K | -17,663 | Closed |
|
|
CCM
30
Corsair Capital Management
New York
| – | -$28.1K | -14,217 | Closed |
|
IMMX Hedge Fund Activity: Q3 2024 in Review
25 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2024, worth a combined $6.1M — down 30% from $8.77M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IMMX and 0 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $201K. The largest seller was AIGH Capital Management, cutting an estimated $570K.
- 25 institutional investors held Immix Biopharma (IMMX) as of Q3 2024, down from 31 in Q2 2024.
- Funds reported $6.1M of Immix Biopharma stock for Q3 2024, down 30% quarter-over-quarter.
- 0 funds opened new Immix Biopharma positions in Q3 2024 and 6 closed out, a net change of -6 holders.
- The largest Immix Biopharma buyer in Q3 2024 was Vanguard Group, an estimated $201K added.
- The largest Immix Biopharma seller in Q3 2024 was AIGH Capital Management, an estimated $570K sold.
Based on aggregated 13F filings for Q3 2024.